RUNX1 and cancer: MLF1 treatment upregulates the level of C/EBPα by suppressing Trib1 or RUNX1-ETO, which causes the inactivation of myeloid-derived suppressor cells (MDSCs) with potent antitumor responses across different tumor models and cancer patients (48).